Life Expectancy News and Research

RSS

Life expectancy is the expected (in the statistical sense) number of years of life remaining at a given age. It is denoted by e''x'', which means the average number of subsequent years of life for someone now aged ''x'', according to a particular mortality experience.

HFSA's 13th Annual Scientific Meeting focuses on causes and treatment of heart failure

The Heart Failure Society of America's (HFSA) 13th Annual Scientific Meeting convened Sunday, September 13, 2009 at the Hynes Convention Center in Boston. This three-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with this condition.

15 Sep 2009

Physical activity increases longevity

Older adults who continue or begin to do any amount of exercise appear to live longer and have a lower risk of disability, according to a report in the September 14 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Sep 2009

HFSA annual meeting features discussion on David Duncan's quest for personalized medicine

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured a discussion by David Ewing Duncan titled "One Man's Quest for Personalized Medicine." Over the course of one year, Duncan submitted himself to hundreds of tests that could predict and even prevent future illness.

14 Sep 2009

PhRMA concurs with Obama's health care reform

Pharmaceutical Research and Manufacturers of America (PhRMA) President & CEO Billy Tauzin issued the following statement after President Obama's address to a joint session of Congress on health care reform:

11 Sep 2009

CytRx granted patent for molecular chaperone amplifier drug candidate

CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).

10 Sep 2009

Psoriasis Walk organized to support the research and education programs of Psoriasis Cure Now

The first-ever New Jersey Psoriasis Walk will take place in Paramus this Saturday, September 12, 2009, at beautiful Van Saun Park. The walk, to support the research and education programs of the nonprofit Psoriasis Cure Now, will include entertainment, information booths on psoriasis treatments, and a chance to meet and learn from others living with psoriasis and psoriatic arthritis. Janine Natoli of Little Falls is volunteer Chair of the NJ Psoriasis Walk, on the Web at http://www.PsoriasisWalkNJ.org.

9 Sep 2009

AARP/Blue Zones Vitality Project launches "6 Weeks to Longevity" program

People don't want to just live longer; they want to live healthier and more purposeful lives. Now, through the AARP(R)/Blue Zones(R) Vitality Project sponsored by United Health Foundation, people from across America will have the opportunity to add healthy years to their lives by joining the project at AARP.org/BlueZonesProject and signing up for the "6 Weeks to Longevity," which kicks off on September 8, 2009.

4 Sep 2009

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG® Cystic Fibrosis 39 Kit v2.

From Thermo Fisher Scientific Inc. 4 Sep 2009

Research reveals that 21% of death claims are rejected by California's largest private insurers

More than one of every five requests for medical claims for insured patients, even when recommended by a patient's physician, are rejected by California's largest private insurers, amounting to very real death panels in practice daily in the nation's biggest state, according to data released today by the California Nurses Association/National Nurses Organizing Committee.

3 Sep 2009

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

Mortality rate following a heart attack has fallen by more than 50% in Europe over the past 25 years. However, because only minor advances in the medical treatment of AMI are expected over the next decade, it is through organisational changes in the pre-hospital phase that mortality rate will continue this decline to below 5%.

2 Sep 2009

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Knopp Neurosciences Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of KNS-760704 in amyotrophic lateral sclerosis (ALS).

2 Sep 2009

Actelion launches new 20 mcg/mL Ventavis formulation

Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.

2 Sep 2009

State wrap: Mental illness in Arizona, stimulus "windfall" in Texas, Medicaid expansion in Nebraska

Local newspapers report on health care issues including mental health in Arizona, the stimulus "windfall" in Texas and a family health insurance plan in Nebraska.

1 Sep 2009

Brits defend National Health Service against U.S. criticism

The United Kingdom's National Health System enters into the health care debate amid comparisons of the British and American health care systems. Meanwhile, British politicians defend NHS against critics.

23 Aug 2009

HeartWare achieves enrollment milestone under its ADVANCE Clinical Trial in the U.S

HeartWare International, Inc. (Nasdaq: HTWR - ASX: HIN) today announced that HeartWare has surpassed 50 implants in the United States under its ADVANCE Clinical Trial, marking an important early enrollment milestone.

21 Aug 2009

Chemical components of elderberry, cinnamon and green tea extracts block HIV viruses from infecting cells

The development of new antiviral drugs has had a tremendous impact on the quality of life and life expectancy of HIV-positive and AIDS patients, as the drugs effectively disrupt the replication cycle of the HIV virus. Yet the regular use of those drugs - such as zidovudine (also known as azidothymidine or AZT), protease inhibitors, and highly active antiretroviral therapy (HAART) involving multidrug therapies - has led to resistant HIV strains.

20 Aug 2009

Newly discovered anti-aging gene linked to high blood pressure

Researchers at the University of Oklahoma Health Sciences Center have shown the first link between a newly discovered anti-aging gene and high blood pressure. The results, which appear this month in the journal Hypertension, offer new clues on how we age and how we might live longer.

19 Aug 2009

The Parkinson's Disease Foundation and the Davis Phinney Foundation jointly fund new study

The Davis Phinney Foundation, a non-profit organization dedicated to improving the lives of people with Parkinson's disease (PD) today, announced that it has awarded four Parkinson's disease research centers with support to conduct a landmark study on the long-term changes in quality of life and mobility that occur in people with PD. The results of this research will help to advance the understanding of how interventions, such as exercise, impact changes in quality of life and mobility over the course of the disease.

19 Aug 2009

Knopp Neurosciences to present phase 2 results of drug candidate in amyotrophic lateral sclerosis

Knopp Neurosciences Inc. said the results of a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (ALS) will be presented at the 20th International Symposium on ALS/MND in Berlin on December 9, 2009.

11 Aug 2009

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Prostate Cancer Early Detection incorporating the results of the recent ERSPC trial that assessed the benefit of PSA screening. The NCCN Guidelines contend that PSA screening does save lives when performed intelligently in men at high-risk of developing the disease.

11 Aug 2009

Life Expectancy News and Research

Further Reading

HFSA's 13th Annual Scientific Meeting focuses on causes and treatment of heart failure

Physical activity increases longevity

HFSA annual meeting features discussion on David Duncan's quest for personalized medicine

PhRMA concurs with Obama's health care reform

CytRx granted patent for molecular chaperone amplifier drug candidate

Psoriasis Walk organized to support the research and education programs of Psoriasis Cure Now

AARP/Blue Zones Vitality Project launches "6 Weeks to Longevity" program

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

Research reveals that 21% of death claims are rejected by California's largest private insurers

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Actelion launches new 20 mcg/mL Ventavis formulation

State wrap: Mental illness in Arizona, stimulus "windfall" in Texas, Medicaid expansion in Nebraska

Brits defend National Health Service against U.S. criticism

HeartWare achieves enrollment milestone under its ADVANCE Clinical Trial in the U.S

Chemical components of elderberry, cinnamon and green tea extracts block HIV viruses from infecting cells

Newly discovered anti-aging gene linked to high blood pressure

The Parkinson's Disease Foundation and the Davis Phinney Foundation jointly fund new study

Knopp Neurosciences to present phase 2 results of drug candidate in amyotrophic lateral sclerosis

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News